Welcome to our dedicated page for Kezar Life Sciences SEC filings (Ticker: KZR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kezar Life Sciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kezar Life Sciences's regulatory disclosures and financial reporting.
Kezar Life Sciences is a clinical-stage biotech company centered on zetomipzomib, a first‑in‑class selective immunoproteasome inhibitor for severe autoimmune diseases, particularly autoimmune hepatitis (AIH). After failing to align with the FDA on a registrational AIH trial in 2025, the company began restructuring and winding down operations while exploring strategic alternatives such as mergers, partnerships or asset sales.
In 2026, Kezar held a successful Type C meeting in which the FDA agreed on key elements of a potential global Phase 2b AIH trial, including treatment duration, endpoints and enrollment criteria, and provided guidance on safety monitoring. Prior AIH data from the PORTOLA Phase 2a trial showed higher rates of complete biochemical remission with steroid taper and some steroid‑free remission versus placebo, with mainly manageable injection‑related side effects.
The lupus nephritis PALIZADE Phase 2b trial was placed on clinical hold and later terminated after serious adverse events, including four fatalities, and Kezar subsequently stopped its Sec61 oncology program. In March 2026, the company sold all Sec61‑related assets, including KZR‑261, to Enodia Therapeutics. Kezar maintains key licenses with Onyx and a regional collaboration with Everest for zetomipzomib and holds a global patent estate extending into the 2030s. As of March 2026 the company had 9 employees and emphasizes significant business, clinical, regulatory and financing risks while it evaluates strategic options.
Kezar Life Sciences has sold its Sec61-based discovery and development program, including preclinical candidate KZR-261, to Enodia Therapeutics. Kezar received $800,000 at closing and is due an additional $200,000 tied to delivery of inventory or 45 days after closing.
The deal also includes up to $127,000,000 in development, regulatory and commercial milestone payments, plus single digit tiered royalties on future net sales of products derived from the acquired assets. Enodia assumed specified liabilities linked to transferred contracts and the acquired assets, while both parties agreed to customary indemnification capped at $1,000,000 for non-fraud losses.
The transaction carves out only the Sec61 program; Kezar retained its zetomipzomib program, employee contracts, cash, receivables, real property and equipment. A joint press release announcing the deal was issued on March 12, 2026.
Kezar Life Sciences, Inc. received an amended Schedule 13G/A from Stonepine-affiliated investors reporting a modest ownership position in its common stock. Stonepine Capital Management, Stonepine Capital, Stonepine GP and Jon M. Plexico together report beneficial ownership of 156,179 shares, representing 2.1% of the class.
All reporting persons have shared voting and dispositive power over these shares and no sole power. They indicate the securities were not acquired and are not held to change or influence control of Kezar Life Sciences and state their ownership is below 5% of the outstanding common stock.
Kezar Life Sciences, Inc. received an updated ownership disclosure from BML Investment Partners, L.P. in Amendment No. 2 to a Schedule 13G. As of the event date of December 31, 2025, BML Investment Partners reported beneficial ownership of 720,787 shares of Kezar common stock, representing 9.8% of the class.
The filing shows BML Investment Partners has shared voting and dispositive power over all 720,787 shares and no sole power. BML Investment Partners is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC, managed by Braden M. Leonard, who is deemed an indirect owner. The reporting persons certify the shares are held on a passive basis, not to change or influence control of Kezar.
Kezar Life Sciences (KZR) reported Q3 2025 results with a net loss of $11.2 million (loss per share $1.53), reflecting sharply lower operating expenses as R&D declined to $6.9 million from $16.2 million a year ago. Cash, cash equivalents and marketable securities totaled $90.2 million as of September 30, 2025, and total stockholders’ equity was $83.0 million.
Management stated existing liquidity is expected to fund operations for at least 12 months. After quarter end, the company repaid $6.3 million to fully retire its Oxford Finance loan and extended its stockholder rights plan. Kezar is exploring strategic alternatives and reduced its workforce by ~70%, estimating $6.0 million in severance and related cash costs, largely recognized in Q4 2025. The company also disclosed it was unable to align with the FDA on a potential registrational AIH study and the FDA cancelled a planned Type C meeting.
Shares outstanding were 7,323,106 as of September 30, 2025; 7,323,156 were outstanding as of November 10, 2025.
Kezar Life Sciences (KZR) announced a major restructuring, reducing its workforce by approximately 31 employees, or about 70%, in connection with its evaluation of strategic alternatives.
The company estimates cash expenditures of about $6.0 million for one-time severance, benefits, and related costs, with the majority of these charges expected to be recognized in the fourth quarter of 2025. Management noted that actual costs could differ materially and that additional charges may arise depending on subsequent events.
Kezar Life Sciences (KZR) repaid its debt under a prior loan agreement and terminated the facility. On October 20, 2025, the company used cash on hand to repay $6.3 million, covering the aggregate outstanding amount, accrued interest, and exit fees under its November 4, 2021 Loan and Security Agreement with Oxford Finance LLC and related lenders. Following repayment, the agreement was terminated and all liens and security interests were released.
This action removes obligations tied to the loan and releases collateral, simplifying Kezar’s capital structure.
Kezar Life Sciences (KZR) disclosed two actions. The company announced a regulatory update on its zetomipzomib program in autoimmune hepatitis and said it plans to explore strategic alternatives. It also reported preliminary cash, cash equivalents and marketable securities of $90.2 million as of September 30, 2025.
The company entered into Amendment No. 2 to its Rights Agreement. The amendment extends the Final Expiration Date to the day following certification of voting results at the 2026 annual meeting, or, if stockholders approve or ratify the Rights Agreement at that meeting, to the day following certification of voting results at the 2027 annual meeting, unless the Rights are earlier redeemed or exchanged.
Stonepine Capital and related parties reported ownership of 377,240 shares of Kezar Life Sciences, Inc. common stock, representing 5.2% of the outstanding shares. The Schedule 13G, signed 09/08/2025, shows the stake is held with shared voting and dispositive power and no sole voting or dispositive power. The percentage is calculated using 7,323,106 shares outstanding as of August 8, 2025. The filing states the reporting persons are filing jointly but disclaim membership in a group and certify the shares were not acquired to change or influence control of the issuer.
Kezar Life Sciences reported continued operating losses while reducing cash burn. For the six months ended June 30, 2025 the company recorded a $30.3 million net loss versus $43.2 million a year earlier; the three‑month loss was $13.7 million. Cash, cash equivalents and marketable securities totaled $100.8 million, and management believes these resources are sufficient to fund operations for at least 12 months from issuance of the financial statements. The company carried an accumulated deficit of $464.8 million.
Operating changes reflect a strategic refocus: research and development expense fell to $21.8 million for six months (from $33.5 million) after termination or completion of several trials, including the PALIZADE program and discontinuation of KZR‑261. Kezar recognized an upfront $7.0 million payment from its Everest collaboration and has potential milestone payments up to $125.5 million plus tiered royalties. Debt outstanding totaled a principal of $7.391 million (net debt $7.921 million) with principal repayments scheduled through 2026. In July 2025 the FDA removed a partial clinical hold on the completed PORTOLA trial and Kezar requested a Type C meeting to discuss AIH development plans.